Thanks for the reminder Kelsee. I made a short post a couple weeks back when this first appeared on their Q1 events. Here is the text from that post. Should be a good event.
--------------
One of the Q1 events is a Keystone Symposia (see event details below). Keystone Symposia are GREAT scientific meetings. Norm Wong presents on February 2nd discussing BET inhibitors in cardiovascular disease AND rheumatoid arthritis. It's been a while since we've heard from either Resverlogix or Zenith on their arthritis program. Hopefully that is a sign that the arthritis program is still alive and well.
Epigenetics and Human Disease: Progress from Mechanisms to Therapeutics
January 29—February 2, 2017
Sheraton Seattle Hotel, Seattle, Washington, USA
Thursday February 2
Norm Wong, Resverlogix Corporation, Canada
Short Talk: Selective BET Inhibitors are Useful for Normalizing Inflammation Leading to Reduced Cardiovascular Disease (CVD) in Humans and in an Animal Model of Rheumatoid Arthritis
